Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum (NYSE:AZN) | Seeking Alpha
AstraZeneca PLC is a high-quality compounder leveraging mid-single-digit revenue growth into robust EPS gains. Read why AZN stock's valuation looks fair.
seekingalpha.com